ImmunoCellular Therapeutics, Ltd Announces Issuance of Japanese Patent Covering Its Lead Antibody Product Candidate ICT-109 For Treatment of Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today the issuance of a Japanese patent relating to the company’s monoclonal antibody therapeutics. Patent No. 4287147, entitled “Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer,” covers the use of IMUC’s proprietary antibodies in diagnosing and treating patients with small cell lung cancer (SCLC) using the company’s lead antibody product candidate, ICT-109. This latest issuance builds on IMUC’s existing patent portfolio in U.S. and international jurisdictions for both the detection and treatment of multiple types of cancer.